Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...
pharmaphorum1d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.
PsyPost on MSN2d
Metabolic signature of depression found in blood, revealing biological links to the disorder
A large-scale study published in Molecular Psychiatry has uncovered a distinct pattern of biological changes in people with ...
I’m a pharmacist — these 6 medications will ‘low-key make you fat’
While the bulk (pun intended) of news coverage these days is focused on GLP-1 drugs like Ozempic that cause weight loss, licensed pharmacist Dr. Kati Forbes told The Post four medications are ...